On October 13th, Danish pharmaceutical company Novo Nordisk announced on its official website that based on a fixed exchange rate (CER), sales for the first nine months of 2023 increased by 33% year-on-year, and operating profit increased by 37% year-on-year. In addition, due to strong demand for weight loss pills driving sales growth, Novo Nordisk has once again raised its annual sales and operating profit expectations. The company expects annual sales to increase by 32% -38% and operating profit to increase by 40% -46%.